Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
October 13 2021 - 8:00AM
Business Wire
- Twist Bioscience to Offer Clinically
Validated, Expert-Designed Exome Panel that Enriches Loci Relevant
to Cancer, Rare and Inherited Diseases -
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced an agreement with
the Broad Institute for the distribution of a customized
next-generation sequencing (NGS) target enrichment exome panel
designed for the identification and research of a wide range of
cancer, rare and inherited disease genes from patient samples.
Twist will market this expert-developed exome panel as the Twist
Alliance Clinical Research Exome.
The Twist Alliance Clinical Research Exome helps support the
Broad Institute Genomics Platform and was designed using validated
data from clinical patient samples. The panel leverages Twist’s
flexible NGS platform to easily and quickly customize content,
resulting in a comprehensive survey of the exome with supplemental
enrichment of clinically relevant areas of the genome related to
cancer as well as rare and inherited diseases. By leveraging the
best-in-class uniformity of Twist NGS probes, the assay enables a
per sample cost and throughput efficiency that Broad has already
leveraged to process more than 250,000 samples to date, keeping it
on the leading edge of exome sequencing.
“Exome sequencing has long been a key part of our sequencing
efforts for large cancer and germline research studies. Our
development with Twist has leveraged many of our learnings on the
technical side and pulls in knowledge from collaborating
investigators to provide an enhanced exome that will increasingly
span both research and clinical applications in which results are
returned to patients” said Stacey Gabriel, senior director of the
Broad Institute Genomics Platform.
The Twist Alliance Clinical Research Exome will be available for
customers in mid-October. The full design of this panel includes
the Twist Core exome, the mitochondrial genome, and additional
validated coding and non-exonic regions of interest such as the
ACMG73 genes, supplemental coverage of regions from OMIM and
COSMIC, and specific Broad-defined targets. To see Broad’s Director
of Genomics Research and Development Brendan Blumenstiel presenting
data on the panel, visit:
https://www.youtube.com/watch?v=v_9Bt8sBuaY.
“Typically, in cancer research studies, there is a great need to
focus sequencing efforts on particular genes or mutations but often
with a small number of samples available. Leveraging the Broad’s
vast expertise, together we have developed a specialized custom
panel that enables deeper sequencing, producing validated genetic
variants that could be used for therapeutic intervention,” said
Emily M. Leproust, PhD, chief executive officer and co-founder of
Twist Bioscience. “We are thrilled to bring this important tool to
our customers to drive deep insights into research and potentially
therapeutic development.”
About Twist Alliance Panels
In partnership with leading research institutions from around
the world, Twist has curated a collection of high-quality target
enrichment panels for applications ranging from carrier screening
to cancer diagnostics and whole exome sequencing. The Twist
Alliance Panels combine the strengths of precise, highly uniform
oligonucleotide synthesis with the specialty expertise of leading
scientific research partners.
Well designed, custom target enrichment panels enable increased
sequencing depth on target genes while reducing overall sequencing.
This allows for more sensitive detection of target sequences and
higher confidence variant detection.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021 and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211013005302/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925- 202-6211 media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Sep 2023 to Sep 2024